Multi-head contrast media injectors offer flexible contrast media management, simplified workflows and increased patient safety.
Contrast delivery is much more controlled and efficient when using a dual-head CT power injector. These medical devices are needed to enable the short imaging times typical of multidetector computed tomography (CT) scanners.
Triple-head injectors allow selection of a second contrast agent when two different contrast agents are used, or switching to full contrast agent containers when two identical contrast agents are used.

See also Contrast Media Injector, Syringeless CT Power Injector, Single-Head Contrast Media Injector, CT Power Injector.

(MPI) The myocardial perfusion scan is the most common nuclear medicine procedure in cardiac imaging and allows assessing the blood-flow patterns to the heart muscles. The comparison of the radiopharmaceutical distribution after stress and at rest provides information on myocardial viability and cardiac perfusion abnormalities. ECG-gated myocardial perfusion imaging allows the assessment of global and regional myocardial function such as wall motion abnormalities.
The diagnostic accuracy of myocardial perfusion scintigraphy (also abbreviated MPS) allows reliable risk stratification and guides the selection of patients for further interventions, such as revascularization. MPI also has particular advantages over alternative techniques in the management of a number of patient subgroups, including women, the elderly, and those with diabetes. The use of this type of cardiac scintigraphy is associated with greater cost effectiveness of treatment, in terms of life-years saved, particularly in these special patient groups.
Myocardial perfusion scintigrams are acquired with a gamma camera. Single photon emission computed tomography (SPECT) is preferred over planar imaging because of the three dimensional nature of the images and their superior contrast resolution.
Common MPI radiopharmaceuticals, approved by the U.S. Food and Drug Administration (FDA) include: Tl-201 and the Tc-99m-labeled radiopharmaceuticals, such as sestamibi, tetrofosmin, and teboroxime for single-photon imaging. Rb-82 is used for positron emission tomography (PET) imaging.

See also Gated Blood Pool Scintigraphy, Myocardial Late Enhancement, Cardiac MRI and Echocardiography.

N1177 is the codename for a nanoparticulate contrast agent under development. N1177 is tested to improve the clinical utility of computed tomography (CT) to diagnose cardiovascular diseases and cancers. N1177 is water insoluble, has an iodine concentration of 67 mg/mL and interacts with activated macrophages. The provider is Nanoscan Imaging, Lansdale, PA.

Omnipaque is a low-osmolar, nonionic, contrast medium with a broad range of indications, for example intravascular diagnostic procedures such as coronary angiography, spinal cord imaging, and body cavity procedures including shoulder and knee joints. Omnipaque is approved for use in adults and children, and is available in a wide variety of packagings.

See also Nonionic Contrast Agents.

Omnipaque (iohexol) is a nonionic, low-osmolar contrast agent and is also available for oral use, offering gastrointestinal (GI) visualization with minimal side effects. Omnipaque has a neutral taste that even kids will drink.
Orally administered iohexol is poorly absorbed from the normal gastrointestinal tract. Omnipaque is well tolerated and absorbed if leakage into the peritoneal cavity occurs.
The recommended dosage of undiluted Omnipaque (at a concentration of for example 350 mg/mL) for computed tomography of the abdomen in adults is 500 mL to 1000 mL, diluted to concentrations of 6 mg/mL to 9 mg/mL. The oral dose should be administered about 20 to 40 minutes prior to the CT scan.